Jose F. Suarez's research while affiliated with University of Miami Miller School of Medicine and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (7)
The use of left ventricular assist devices (LVADs) is increasingly more common as the availability of donor organs in relation to failing hearts is outstandingly limited. Infections are the most common complications in LVAD recipients, particularly those caused by Staphylococcus spp. Refractory LVAD‐related infections are not uncommon as achieving...
The recent randomized controlled trial by Arreola‐Guerra et al on the use of fosfomycin trometamol (FOS) in the primary prevention of urinary tract infections (UTI) in kidney transplant recipients (KTR) found no difference in the incidence of UTI or the median time to UTI. Although in their study, FOS was not beneficial for the overall prevention o...
Background: Antiretroviral therapy (ART) poses challenging drug-drug interactions with immunosuppressant agents in transplant recipients. We aimed to determine the impact of specific antiretroviral regimens in clinical outcomes of HIV ⁺ kidney transplant recipients. Methods: A single-center, retrospective cohort study was conducted at a large acade...
Background:
HIV infection is associated with high rates of acute rejection following kidney transplantation. The underlying mechanisms for such predisposition are incompletely understood. Pathological immune activation is a hallmark of chronic HIV infection that persists despite effective antiretroviral therapy. We hypothesized that the baseline l...
Citations
... Recent experiences with using antistaphylococcal beta-lactam antibiotics combined with a carbapenem to clear persistent MSSA bacteremia in adults have raised hope that such an antimicrobial approach could also be successfully applied in preterm infants. [4][5][6][7] We review here our experience with 2 cases, and 1 previously reported. 8 ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1167661471928322-1655403597678_Q64/Gabriel-Motoa.jpg)
... Three groups were compared, a pre-BCID period (n = 52), after BCID and before the ASP intervention (post-BCID, n = 43), and after the BCID and ASP intervention (post-ASP, n = 35). There was no significant difference in time to appropriate therapy (before BCID: Moreover, a retrospective study by Rosa et al. of 95 patients with hematologic malignancies or bone marrow transplantation showed no benefits over time for appropriate therapy using multiplex PCR blood panel identification alone or in conjunction with the ASP intervention [28]. There are limitations that may explain the non-benefit of BCID combined with ASP strategies, e.g., the general lack of understanding of these technologies among health workers. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/273780605976581-1442285791151_Q64/Rossana-Rosa.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272209402920983-1441911187319_Q64/Lilian-Abbo.jpg)
... Los inhibidores de la integrasa no son metabolizados por la citocromo P450 o la glicoproteína P, lo que evita las interacciones farmacológicas complejas y permite su administración de forma segura en los pacientes trasplantados VIH+ (31,40,59,(71)(72)(73)(74). Es por esto que los regímenes basados en inhibidores de la integrasa son los de elección en los pacientes trasplantados VIH+ (22). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/466345423839235-1488196821862_Q64/Jose-Camargo-7.jpg)
... About 90 % of these cases involve the use of autografts or allografts, the two "gold-standards" in the field [1]. However, the usage of autografts is expensive, and often associated with donor-site morbidity, whereas allografts introduce the risk of viral transformation and infection and can induce immunological rejection by the host [2]. To overcome these limitations, significant effort has been devoted to developing synthetic substitutes for bone implants. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272294090113030-1441931378249_Q64/Phillip-Ruiz-2.jpg)
